Published November 27, 2020 | Version v1
Software Open

How to predict relapse in leukaemia using time series data: A comparative in silico study.

  • 1. Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, School of Medicine, TU Dresden, 01307 Dresden, Germany
  • 2. Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, School of Medicine, TU Dresden, 01307 Dresden, Germany; AICURA medical GmbH, 12103 Berlin, Germany
  • 3. Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, School of Medicine, TU Dresden, 01307 Dresden, Germany; National Center of Tumor Diseases (NCT), Partner Site Dresden, 01307 Dresden, Germany
  • 4. Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, School of Medicine, TU Dresden, 01307 Dresden, Germany; Max Planck Institute for Human Cognitive and Brain Sciences, 04103 Leipzig, Germany

Description

Risk stratification and treatment decisions for leukaemia patients are regularly based on clinical markers determined at diagnosis, while measurements on system dynamics are often neglected. However, there is increasing evidence that linking quantitative time-course information to disease outcomes can improving the predictions for patient-specific treatment response.

We analyzed the potential of different computational methods to accurately predict relapse for chronic and acute myeloid leukaemia, particularly focusing on the influence of data quality and quantity. Technically, we used clinical reference data to generate in-silico patients with varying levels of data quality. Based hereon, we compared the performance of mechanistic models, generalized linear models, and neural networks with respect to their accuracy for relapse prediction. We found that data quality has a higher impact on prediction accuracy than the specific choice of the method. We further show that adapted treatment and measurement schemes can considerably improve prediction accuracy. Our proof-of-principle study highlights how computational methods and optimized data acquisition strategies can improve risk assessment and treatment of leukaemia patients.

Files

aml-cml-relapse-prediction-method-comparison.zip

Files (563.7 MB)

Name Size Download all
md5:b3fa10d27d19135ac983a201e6ec4815
563.7 MB Preview Download

Additional details